ABMD — Abiomed Income Statement
0.000.00%
Last trade - 00:00HealthcareAdventurousLarge Cap
- $17.18bn
- $16.36bn
- $1.03bn
Annual income statement for Abiomed, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2018 March 31st | 2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 594 | 769 | 841 | 848 | 1,032 |
| Cost of Revenue | |||||
| Gross Profit | 495 | 640 | 690 | 686 | 844 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 437 | 545 | 596 | 618 | 891 |
| Operating Profit | 157 | 225 | 245 | 230 | 141 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 160 | 263 | 257 | 288 | 191 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 134 | 259 | 203 | 226 | 137 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | 112 | 259 | 203 | 226 | 137 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 112 | 259 | 203 | 226 | 137 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 2.91 | 5.61 | 4.51 | 4.94 | 5.18 |